[{"id":"de421412-fb86-418c-a6aa-0a09654defc6","acronym":"DSP-5336-101","url":"https://clinicaltrials.gov/study/NCT04988555","created_at":"2021-08-03T18:53:07.117Z","updated_at":"2024-07-02T16:35:23.111Z","phase":"Phase 1/2","brief_title":"A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation","source_id_and_acronym":"NCT04988555 - DSP-5336-101","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" FLT3 • IDH1 • IDH2 • NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • MLL fusion","tags":["FLT3 • IDH1 • IDH2 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enzomenib (DSP-5336) • Noxafil (posaconazole)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/28/2022","start_date":" 02/28/2022","primary_txt":" Primary completion: 01/02/2025","primary_completion_date":" 01/02/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-01-18"}]